Clinical Trials Sponsored by Geert Wanten

Total 1930 results

Geert Wanten
Geistlich Pharma AG

Completed

Clinical Trial With Catheter Locking TauroSept® (Taurolidine 2%) or Saline Solution 0,9%

Catheter Related Blood Stream Infections

United Kingdom, Israel, Denmark, Germany, Italy, Netherlands
Geert Wanten
Baxter Healthcare Corporation

Completed

Essential Fatty Acid Status & Immune Function in Parenteral Nutrition Patients

Intestinal Failure

Netherlands
Geert Meyfroidt, MD, PhD

Completed

Acute Kidney Injury Predictor Validation Study (AKIpredValid)

Critical Illness | Acute Kidney Injury

Belgium
GlaxoSmithKline
Prof Geert D'Haens, AMC, Amsterdam

Terminated

Safety and Tolerability Study of GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis.

Colitis, Ulcerative

Netherlands
Asten Sante

Recruiting

Consequences of Respiratory Devices on Caregivers (CAP2) (CAP2)

Quality of Life

France
University Hospital, Basel, Switzerland
Gebert Rüf-Stiftung

Active, not recruiting

Developing Microbials to Fight Extended-spectrum Beta-lactamase (ESBL)-Producing Escherichia Coli

Extended Spectrum Beta Lactamases (ESBL) E. Coli

Switzerland
Geert D'Haens
Takeda

Completed

A Study to Evaluate Efficacy, of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study (LOVE-CD)

Crohn Disease

Belgium, Netherlands, Hungary
Geert D'Haens
Takeda

Completed

An Open Label Phase 4 Study to Evaluate Efficacy of Early Versus Late Use of Vedolizumab in Ulcerative Colitis (LOVE-UC)

Colitis, Ulcerative

Netherlands, Belgium, Hungary
Asten Sante
Slb Pharma; Withings; Nouvéal

Recruiting

Impact of Patient Involvement in Alerts Management of Telemonitoring CPAP

OSA

France
Geert D'Haens
Bristol-Myers Squibb

Not yet recruiting

Ulcerative Colitis Leukocyte TRAfficking After Treatment With Zeposia: the ULTRAZ Study (ULTRAZ)

Ulcerative Colitis
Santen SAS

Completed

A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Surface Disease | Open-Angle Glaucoma or Ocular Hypertension

France
Santen SAS

Completed

Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis (FAST)

Keratitis

France
Santen Inc.

Terminated

LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

Non Infectious Uveitis

United States, India, Italy, Argentina
Santen SAS

Completed

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)

Conjunctivitis, Vernal

France
Santen Inc.

Completed

A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

Open-angle Glaucoma, Ocular Hypertension

United States, Japan
Santen Inc.

Completed

Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6

Primary Open-angle Glaucoma and Ocular Hypertension

United States
Santen SAS

Completed

NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye

Dry Eye

United States
Santen SAS

Completed

Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

Diabetic Macular Edema

United States
Santen Inc.

Completed

Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease

Dry Eye

United States
Santen Inc.

Completed

A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Dry Eye Disease

United States
Santen Inc.

Completed

Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

United States
Santen Inc.

Completed

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States
Santen SAS

Completed

Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome

Moderate to Severe Dry Eye Syndrome

France
Santen Inc.

Completed

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study

Glaucoma and Ocular Hypertension

United States
Santen SAS

Completed

Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis

Vernal Keratoconjunctivitis

United States, Croatia, France, Germany, Greece, Hungary, India, Israel, Italy, Portugal, Spain
Santen Inc.

Completed

Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects

Age-Related Macular Degeneration

United States, Philippines
Santen Inc.

Completed

A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program (SPRING)

Non-Infectious Uveitis of the Posterior Segment of the Eye

United States, France, Turkey, Italy, Austria, India
Santen Inc.

Completed

Study Assessing Double-masked Uveitis Treatment (SAKURA)

Uveitis; Posterior, Disorder

United States, France, Italy, Poland, United Kingdom, Germany, Spain, Austria, Colombia, Israel, India, Turkey, Japan, Peru, Argentina, Brazil, Chile
Santen Inc.

Completed

A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration (VAPOR1)

Age-Related Macular Degeneration

United States
Santen Oy

Completed

A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United Kingdom, United States
Santen SAS

Completed

Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease

Ocular Hypertension | Glaucoma | Ocular Surface Disease

United States
Santen Oy

Completed

Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops

Ocular Hypertension | Open-Angle Glaucoma
Santen Oy

Completed

Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops

Healthy Volunteers

Finland
Santen Oy

Completed

Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations

Ocular Hypertension | Open-angle Glaucoma

Hungary
Santen Inc.

Completed

Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Dry Eye

United States
Santen Oy

Completed

Interaction Study of Timolol Eye Drops and Paroxetine Capsules

Healthy

Finland
Technische Universität Dresden
Gert und Susanna Mayer Stiftung

Recruiting

Neurocognitive Function After Proton Therapy in Children and Adolescents (ELBE-ProKids)

Primary Brain Tumor

Germany
Gert Meijer
M.D. Anderson Cancer Center

Completed

PReoperative Identification Of Response to Neoadjuvant Chemoradiotherapy for Esophageal Cancer (PRIOR)

Esophageal Cancer

United States, Netherlands
Santen SAS

Recruiting

3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (PROSIKA)

Dry Eye Syndromes

Spain, France, Poland
Santen SAS

Recruiting

3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (ALHENA)

Dry Eye Syndromes

France
Santen Inc.

Completed

Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia (OPSIS)

Presbyopia

United States
Santen SAS

Completed

3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)

Dry Eye Disease With Severe Keratitis

Czechia, France, Italy, Poland, Russian Federation, Spain, Turkey
Santen Inc.

Completed

DE-117 Spectrum 5 Study

Primary Open-angle Glaucoma and Ocular Hypertension

United States
Santen Inc.

Completed

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

Glaucoma and Ocular Hypertension

United States
Santen Inc.

Completed

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension (ANGEL-2)

Primary Open Angle Glaucoma | Ocular Hypertension

United States
Santen Inc.

Completed

A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration (PAVE)

Age-Related Macular Degeneration

United States
Santen Inc.

Completed

Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SEE-1)

Ocular Hypertension | Open-angle Glaucoma

United States
Santen Inc.

Completed

Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Open-angle Glaucoma or Ocular Hypertension

United States
Santen Inc.

Completed

A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration

Age-Related Macular Degeneration

United States
Santen Inc.

Completed

A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT

Glaucoma and Ocular Hypertension

United States

3

Subscribe